- Home
- BODI vs LUNG Comparison
BODI vs LUNG Comparison
Compare BODI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BODI | LUNG |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.2M | 72.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BODI | LUNG |
|---|---|---|
| Price | $8.70 | $1.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $8.00 | $6.81 |
| AVG Volume (30 Days) | 35.4K | ★ 308.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $83,789,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.01 |
| 52 Week Low | $3.38 | $1.31 |
| 52 Week High | $12.66 | $9.35 |
Technical Indicators
Market Signals| Indicator | BODI | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 37.58 | 32.51 |
| Support Level | $8.28 | $1.38 |
| Resistance Level | $12.66 | $1.52 |
| Average True Range (ATR) | 0.78 | 0.10 |
| MACD | -0.30 | 0.00 |
| Stochastic Oscillator | 11.87 | 12.66 |
Price Performance
Historical ComparisonAbout BODI The Beachbody Company Inc.
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.